Indeed, C/EBPδ levels are diminished in hepatocellular carcinoma, pancreatic ductal adenocarcinoma (PDAC), ovarian cancer, breast cancer and cervical cancer, and low C/EBPδ levels associate with poor survival in these cancers [7, 8, 9, 10, 11, 12, 13, 14, 15]. This evidence concerns the gene CEBPD and breast carcinoma.